#RETHINK HEALTH

With an ageing population, increasing life expectancy and exploding health costs, it is time to rethink. FUTRUE is the incubator for tomorrow's trends. With now more than 20 companies and over 70 drug approvals, we are active in areas such as intelligent bacteria, innovative pain therapies, chemical-free drugs, medical cannabis, dermaceuticals, functional food and e-health. Many of our companies are among the fastest growing healthcare companies in Europe. In doing so, we rely on a new generation of dynamic talents who have the courage to take unusual paths.
  • Employer of a new generation of dynamic talents
  • Incubator of global trends and innovations in healthcare
  • Accelerator with national and international structures
  • Arbeitgeber einer neuen Generation dynamischer Talente

  • Inkubator globaler Trends und Innovationen in Healthcare

  • Accelarator mit nationalen und internationalen Strukturen

FUTRUE now comprises over 20 companies active in areas such as intelligent bacteria, innovative pain therapies, chemical-free drugs, medical cannabis, dermaceuticals, functional food and e-health. A selection of our companies at a glance:

Remitan
Vertanical
E-HEALTH
EMCM - agentur für media und kommunikation

PRODUCTS

FUTRUE has more than 70 drug approvals across the Group as well as a large number of medical and functional food products. Numerous products are currently undergoing approval procedures or clinical trials. Below you can see a selection of our leading preparations at a glance:

RubaXX
FULMINAN
Vertanical
Restaxil

ERFOLGE

2008 Sale of the e-detailing platform 123MID to Novartis
2008 Sale of physician evaluation platform Docya to Novartis
2011 Launch of the blockbuster Kijimea Reizdarm (Synformulas)
2013 Sale of Lactostop (Naturwohl Vertrieb) to Dermapharm
2014 Launch of the blockbuster Rubaxx (PharmaSGP)
2015 Presence in all major European and North American markets
2015 Sale of diet blockbuster Yokebe (Naturwohl Pharma) to Perrigo
2015 PharmaSGP awarded best OTC company of the year
2017 Most successful OTC launch of the year: Restaxil (PharmaSGP)

MANAGEMENT

Ihre Karriere bei FUTRUE beginnt hier.

Jobs
closechevron-leftchevron-right